The pharmacokinetics and safety of single escalating oral doses of eletriptan

Journal of Clinical Pharmacology

Volumn 42, Issue 5, 2002, Pages 520-527

  Shah, Ajit K ^a,d   Harris, Stephen C ^a   Greenhalgh, Catherine ^b   Morganroth, Joel ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c eResearchTechnology   (United States)

^d GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELETRIPTAN; PLACEBO; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOKINESIA; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; INDOLES; LIVER FUNCTION TESTS; MALE; MOLECULAR STRUCTURE; PYRROLIDINES; SALIVA; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0036230876     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011571     Document Type: Article

References (18)

1. Migraine diagnosis and clinical symptomatology
2. Migraine: Theories of pathogenesis
3. Sumatriptan for the treatment of migraine attacks - A review of controlled clinical trials
4. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan
5. Single dose pharmacokinetics of sumatriptan in healthy volunteers
6. 1D-like" receptor
7. 1D-like" receptor partial agonist
8. Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
9. Comparison of the efficacy of oral eletriptan (20 mg, 40 mg, 80 mg) and sumatriptan (50 mg, 100 mg) for the treatment of acute migraine: Pooled analysis of randomized clinical trials
10. Determination of eletriptan in plasma and saliva using automated sequential trace enrichment of dialysate and high-performance liquid chromatography
11. 1-like agonist GR 43175 in healthy volunteers
12. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers
13. A study to determine the absolute bioavailability of oral naratriptan
14. Oral naratriptan tablets (2.5 mg-10 mg) exhibit dose-proportional pharmacokinetics
15. 1D agonist
16. 1D-like agonists as a predictor of oral absorption potential
17. Use of Caco-2 cell monolayer model to assess the comparative absorption potential of eletriptan and related antimigraine agents
18. The safety and tolerability of sumatriptan: An overview